Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin

Huan Yu
Vincent C Woo
Department of Medicine, Division of Endocrinology and Metabolism, Health Sciences Centre, University of Manitoba, Winnipeg, MB, Canada

Aims: The aim of this article is to review the safety and efficacy data of dapagliflozin, saxagliptin, and their combination in the management of patients with type 2 diabetes. Evidence for the use of the single-tablet combination formulation is also presented.

Methods: A nonsystematic literature review was performed using the Ovid, PubMed, and Google Scholar databases.

Results: The addition of dapagliflozin/saxagliptin to metformin can lower mean hemoglobin A1c by as much as 1.47% and lead to weight loss of 0.5–2.0 kg. The risk of genital infections with combination therapy is lower than observed with dapagliflozin alone, suggestive of a protective effect. Adverse event risk at 52-week follow-up was not increased beyond that seen with either monotherapy.

Conclusion: Dapagliflozin/saxagliptin combination is generally well tolerated and is an effective tool in helping patients with diabetes improve glycemic control.

Keywords: SGLT2 inhibitor, DPP4 inhibitor, single-tablet combination, diabetes mellitus

Introduction
As of 2015, 415 million people around the world have type 2 diabetes (DM2), and this is expected to increase to >600 million by 2040.1 Tight glycemic control can delay or prevent the development of macrovascular2,3 and microvascular complications.4,5 As a progressive disease, patients often need multiple antihyperglycemic agents for adequate control.6 However, many of the diabetes medications are associated with undesirable side effects. Insulin and secretagogues can increase the risk for hypoglycemia and cause weight gain.7 As many as 85% of patients with DM2 are already overweight,8 and weight reduction is a key goal in the management of diabetes as it will reduce insulin resistance and comorbid conditions such as hypertension and dyslipidemia.9 Thiazolidinediones can lead to fluid retention as well as weight gain, and may be unsafe for patients with preexisting heart failure.8 Metformin use may be limited by gastrointestinal side effects or renal insufficiency.10

Given the risks for complications with intensified glycemic control4,11 and the different side-effect profiles of various antihyperglycemic agents, an individualized approach must be taken.12,13 Although metformin remains first-line in conjunction with lifestyle modification, add-on therapy is left up to patient preference and physician judgment.12,13 In their position statement for management of hyperglycemia in DM2, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend initiation of combination therapy if hemoglobin A1c (HbA1c)
is ≥9.0% to achieve target more quickly.6 The Canadian Diabetes Association also recommends initiating combination therapy when HbA1c is ≥8.5%.13 Similarly, the 2015 American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) Comprehensive Diabetes Management Algorithm recommends the initiation of combination therapy if HbA1c is ≥7.5% at diagnosis or if a patient fails to meet glycemic targets after 3 months of monotherapy.14 This recognizes the greater difficulty in achieving glycemic control if added therapy is delayed,12 as prolonged hyperglycemia can result in glucotoxicity, adding to progressive β-cell function loss.15

Whenever combination therapy is required, drugs using different mechanisms of action are recommended.12 The latest guidelines from AACE/ACE and ADA/EASD cite higher level evidence supporting the addition of a dipeptidyl peptidase-4 (DPP4) inhibitor and/or a sodium-glucose cotransporter type 2 (SGLT2) inhibitor.1,6,14 Although SGLT2 inhibitors can increase insulin sensitivity, endogenous glucose production is increased through increased glucagon.16 Conversely, DPP4 inhibitors also increase insulin sensitivity but suppress glucagon, making their pairing mechanistically complementary.17 Single-pill combination of dapagliflozin 10 mg/saxagliptin 5 mg has been developed to capitalize on this advantage.18 Single-tablet combination (STC) pills have been used in many chronic illnesses such as cardiovascular diseases, AIDS, and diabetes.19 By simplifying medication regimen, combination pills have been shown to improve adherence and quality of life.20,21

Dapagliflozin/saxagliptin was the first SGLT2 inhibitor and DPP4 inhibitor combination pill approved in Europe.22 As of February 2017, this medication has also been approved for use by the U.S. Food and Drug Administration (FDA) as an adjunct to lifestyle modification for the management of DM2.23 This article will review the evidence for efficacy and safety of dapagliflozin and saxagliptin as individual and add-on therapy. The five existing phase III studies for their combined use and their role in the management of DM2 are discussed later.

Methods
A nonsystematic search was performed on Ovid, PubMed, and Google Scholar using a combination of keywords, including SGLT2 inhibitor, DPP4 inhibitor, dapagliflozin, saxagliptin, and diabetes. Relevant articles were selected based on title and abstract review. Ongoing clinical trials were identified from www.clinicaltrials.gov for dapagliflozin and saxagliptin, with a special interest for combined use in diabetes. For completeness, references were also mined from key review articles and meta-analyses.

Saxagliptin
Mechanism of action
DPP4 is a class of membrane-bound endopeptidases in a variety of tissues, including the endothelium, liver, and kidneys.24,25 They degrade the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinitropic polypeptide (GIP) secreted in response to oral glucose load.26 GIP and GLP-1 augment and sustain insulin release by sensitizing pancreatic β cells to glucose concentration.26 DPP4 inhibitors increase insulin secretion and GLP-1 levels, thereby suppressing the increased glucagon and hepatic gluconeogenesis that are common in DM2.27,28 Thus, although fasting glucose is reduced by saxagliptin, post-prandial hyperglycemia is more potent inhibited,29 lowering 24-hour glucose levels by an average of 1 mmol/L.28 Although it inhibits gluconeogenesis, by increasing insulin in a glucose-dependent way, DPP4 inhibitors pose minimal hypoglycemia risk.24,27

Pharmacokinetics
Saxagliptin is a highly potent and selective DPP4 inhibitor, increasing circulating levels of GLP-1 and GIP two- to threefold following a meal.27,30 It was approved in 2009 by the FDA for the treatment of DM2 as an adjunct to lifestyle modification, dosed as 2.5 mg or 5 mg once daily.31,32 Oral bioavailability is 67%, with peak concentrations within 2 hours and half-life of 2–4 hours.28,33 Saxagliptin is metabolized by the hepatic cytochrome P450 3A4/5 into the major active metabolite BMS-510849, half as potent as the parent drug but with a longer half-life of 3–7.4 hours,33 allowing for once-daily dosing.34 Parent compound and metabolite are renally cleared.34 Therefore, saxagliptin should be reduced to 2.5 mg if creatinine clearance (CrCl) is ≤50 mL/min or there is concomitant use of strong CYP450 3A4/5 inhibitors (i.e., ketoconazole, ritonavir) to avoid accumulation.32,33

Monotherapy
In clinical studies, saxagliptin monotherapy has been shown to reduce HbA1c by 0.4%–1.1% after 12 weeks, depending on dose and baseline HbA1c.25,27,35,36 Treatment-naïve patients randomized to saxagliptin 2.5 mg and 5 mg achieved placebo-adjusted HbA1c reductions of 0.45%–0.65% and 0.40%–0.73% as well as placebo-adjusted fasting blood glucose (FBG) reductions of 0.76–1.1 mmol/L and 0.78–1.3 mmol/L, respectively, after 12–24 weeks depending on the study.31,35,36 Post-prandial sugars were also reduced, and greater
proportions of patients using saxagliptin achieved HbA1c target of <7% compared with placebo.\textsuperscript{31,35,36} Homeostatic model assessment (HOMA) studies confirmed increased β-cell function.\textsuperscript{31,36} Extended follow-up to 76 weeks still finds sustained placebo-adjusted HbA1c reductions of 0.12%–0.55%.\textsuperscript{35} Weight neutrality and similar hypoglycemia event rates as placebo were demonstrated in studies up to 76 weeks.\textsuperscript{31,35,36}

Jadzinsky et al\textsuperscript{37} compared the efficacy of initiating metformin and saxagliptin 5 mg or 10 mg, with either metformin or saxagliptin 10 mg monotherapy in treatment-naïve diabetic patients. By 24 weeks, mean HbA1c dropped by −2.5% in metformin/saxagliptin groups compared with −2.0% in metformin-only group (p<0.0001) and −1.7% in saxagliptin-only group (p<0.0001).\textsuperscript{37} FBG and postprandial glucose (PPG) were significantly reduced.\textsuperscript{37} No added benefit was seen with saxagliptin 10 mg.\textsuperscript{37} Of note, reductions in HbA1c, FBG, and 2-hour blood glucose level were similar between the metformin- and saxagliptin-monotherapy groups, suggesting comparable efficacy.\textsuperscript{37}

**Add-on therapy**

Efficacy and safety of saxagliptin as an add-on agent to metformin,\textsuperscript{38–41} sulfonylureas,\textsuperscript{41–43} acarbose,\textsuperscript{41} thiazolidinediones,\textsuperscript{41,44,45} and insulin\textsuperscript{46,47} have been established. In general, mean adjusted HbA1c, FBG, and PPG levels were lowered by comparable amounts to saxagliptin monotherapy. Compared against uptitration of metformin (Met-Up), a phase III trial found that saxagliptin 5 mg add-on to submaximal metformin (Saxa-Met) resulted in a similar glycemic control (Met-Up-adjusted mean HbA1c change −0.38±0.06%, Saxa-Met −0.47±0.06%; p=0.260 between group difference).\textsuperscript{40} A greater proportion of Saxa-Met than Met-Up reached HbA1c target of <7% (43.8% vs 35%) and <6.5% (20.5% vs 16.8%).\textsuperscript{40} Greater adverse events were seen in the Met-Up cohort (51.0%, 75/147) compared with Saxa-Met (43.9%, 61/139), predominantly that of diarrhea.\textsuperscript{40}

Compared against uptitration of glyburide, adding saxagliptin to submaximal glyburide resulted in greater HbA1c reduction at 24 weeks (glyburide-adjusted mean −0.62% for saxagliptin 2.5 mg, −0.72% for 5 mg; p<0.0001 compared to uptitration).\textsuperscript{43} Mean FBG was also significantly reduced. In all, 22.4% of the 2.5 mg cohort and 22.8% of the 5 mg cohort achieved HbA1c <7%, compared with 9.1% in uptitrated glyburide (p<0.0001).\textsuperscript{43} When followed for 76 weeks, mean HbA1c increased in all groups, consistent with known loss of efficacy of sulfonylureas over time.\textsuperscript{48} However, glyburide-adjusted mean HbA1c reduction remained statistically significant at −0.59% (95% confidence interval [CI]: −0.86, −0.31) and −0.67% (95% CI: −0.94, −0.39), respectively, and a greater proportion of saxagliptin patients maintained HbA1c <7% at 76 weeks.\textsuperscript{42}

Active comparator studies have demonstrated saxagliptin to be noninferior to glipizide as an add-on therapy to metformin.\textsuperscript{49,50} At 52 weeks, glipizide-adjusted mean HbA1c reduction was −0.06% (95% CI: −0.16, 0.05),\textsuperscript{49} maintained at 104 weeks.\textsuperscript{40} However, saxagliptin group experienced less adverse events (67.1% saxagliptin vs 72.6% glipizide), in particular hypoglycemia (3.5% vs 38.4%).\textsuperscript{50} Glipizide-adjusted mean weight change was also significant at −2.8 kg (95% CI: −3.32, −2.20).\textsuperscript{50}

Saxagliptin add-on to insulin has also been studied.\textsuperscript{46,47} Barnett et al\textsuperscript{46} randomized 455 patients inadequately controlled on stable-dose insulin (total daily dose [TDD] 30–150 U/day) with or without metformin to saxagliptin 5 mg versus placebo. Fast- ing serum glucose did not differ, but postprandial area under curve was reduced with saxagliptin at 24 weeks (p=0.0011).\textsuperscript{46} HbA1c reduction was evident by 12 weeks and sustained at 24 weeks, with placebo-adjusted change of −0.41% (95% CI: −0.59, −0.24; p<0.0001) with saxagliptin, regardless of baseline metformin use.\textsuperscript{46} Weight and risk of hypoglycemia did not differ between groups; however, difference in TDD was only 3.3 U by the end of trial with 17.3% of saxagliptin cohort achieving target HbA1c <7% compared with only 6.7% on placebo,\textsuperscript{46} suggestive of under titration, which may have attenuated the differences in complication.

**Tolerability and safety**

Saxagliptin is generally well tolerated, with a low risk of hypoglycemia given its glucose-dependent effects.\textsuperscript{51–53} In monotherapy and as an add-on agent, adverse event, discontinuation, and hypoglycemia rates were typically low and balanced, without added weight gain.\textsuperscript{31,35,36,40,44} When added to submaximal-dose metformin, saxagliptin produced comparable glycemic control without the increased gastrointestinal side effects with uptitrated metformin.\textsuperscript{40} Compared to glipizide add-on to metformin, saxagliptin had similar efficacy, but with significantly less hypoglycemia and weight gain.\textsuperscript{50} When added to submaximal glyburide, glycemic control significantly improved, with a minimal increase in confirmed hypoglycemia (5.2% with saxagliptin 2.5 mg, 3.2% with saxagliptin 5 mg, and 3.4% with uptitration), and most were only mild or moderate in intensity.\textsuperscript{42}

Hirshberg et al\textsuperscript{51} performed a meta-analysis of 20 placebo and active comparator phase IIb/III trials to examine the safety of saxagliptin. Pooled analysis of 9,156 patients found that saxagliptin and controls had similar incidence rate ratios
(IRRs) of death (2.5 mg dose IRR=0.46, 95% CI: 0.10, –1.82; 5 mg dose IRR=0.73, 95% CI: 0.31, –1.68), serious adverse events (2.5 mg dose IRR=0.96, 95% CI: 0.7, –1.33; 5 mg dose IRR=1.03, 95% CI: 0.84, –1.26), and discontinuation due to adverse events (2.5 mg dose IRR=1.14, 95% CI: 0.74, –1.78; 5 mg dose IRR=1.10, 95% CI: 0.84, –1.43).51 When use of confounding medication (i.e., insulin, sulfonylurea) was excluded, saxagliptin was not associated with increased reported or confirmed hypoglycemia.51 No increased risk for pancreatitis was seen.51 Overall, saxagliptin was felt to have a good safety profile.

SAVOR-TIMI randomized 16,492 patients with increased cardiovascular risk to saxagliptin or placebo.54 After median follow-up of 2.1 years, the primary composite end point of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke occurred in 3.7/100 person-years on saxagliptin and placebo, yielding an HR of 1.00 (95% CI: 0.89, –1.12).54 However, more patients on saxagliptin was hospitalized for heart failure (HR=1.27; 95% CI: 1.07, –1.51; p=0.007).54 Reexamination of data found this risk increased within the first 12 months of therapy (HR=1.52; 95% CI: 1.17, –1.96; p=0.0015), after which there was no difference (HR=1.05; 95% CI: 0.81, –1.35; p=0.73).55 Several clinical risk factors identified patients at a high absolute risk for heart failure, particularly prior history of heart failure (χ²=231.99, adjusted HR=4.18; 95% CI: 3.48, –5.02; p<0.01), estimated glomerular filtration rate (eGFR) ≤60 mL/min (χ²=49.86, adjusted HR=2.00; 95% CI: 1.65, –2.42; p<0.01), urine albumin–creatinine ≥3.4 mg/mmol (χ²=35.77, adjusted HR=1.89; 95% CI: 1.54, –2.34; p<0.01), and elevated baseline N-terminal pro b-type natriuretic peptide (NT-proBNP) levels (stepwise increase with each quartile).55 As yet, there is no identified pathophysiology for the increased risk of hospitalization for heart failure (0.7% absolute risk over 2 years).53,55 No association with volume overload (as evidenced by increased NT-proBNP, weight, or peripheral edema) or myocardial toxicity (via increased hsTNT or hsCRP) was seen in SAVOR-TIMI,45 suggesting saxagliptin safety in cardiovascular patients outside of the aforementioned risk factors.

No renal risks were detected in SAVOR-TIMI, and at the end of trial, more patients in the saxagliptin group showed either lack of progression or even improvement in microalbuminuria;44 the implications for this on long-term cardiovascular outcomes are unknown.51–55 There was no increased risk for pancreatitis,54 as supported by other systematic reviews and meta-analyses.51,56 Although the risk of pancreatic cancer is difficult to assess given the long follow-up required, a meta-analysis of randomized controlled trials that included DPP4 inhibitors, totaling 68,318 patients with 52,464 patient-years, suggested no increased risk compared with placebo or other antihyperglycemic agents (odds ratio [OR]=0.72, 95% CI: 0.32, –1.61; p=0.42).56

Safety in patients aged ≥65 years was assessed in a pooled analysis of five phase III trials, totaling 428 individuals.57 Incidence of adverse events, including hypoglycemia, was similar between treatment and placebo, and unchanged compared to younger subgroups.57 Investigators of SAVOR-TIMI also performed subgroup analysis in elderly (≥65 years) and very elderly (≥75 years) patients, with no difference in primary cardiovascular outcomes between saxagliptin and placebo (elderly HR=0.92; 95% CI: 0.79, –1.06; very elderly HR=0.95; 95% CI: 0.75, –1.22).58 Proportion of hypoglycemia was minimally higher in the saxagliptin group (<65 years, 14.5% vs 12.4% placebo, p=0.006; ≥65 years, 16.0% vs 14.4% placebo, p=0.043), but this was related to background sulfonylurea use and baseline HbA1c <7%.58

Dapagliflozin

Mechanism of action

SGLTs are adenosine triphosphate-dependent, transmembrane glucose transporters. SGLT2s are almost exclusively found in the S1 segment of the proximal renal tubules.59,60 In rodent studies and in healthy individuals, they have been shown to reabsorb ~90% of the average 180 g filtered glucose, with the SGLT1s in the distal proximal tubules reabsorbing the remainder.60,61 As plasma glucose increases, reabsorption increases linearly and then plateaus as SGLTs become saturated. Patients with DM2 have increased number of SGLT2s, but whether this is related to pathogenesis or as a consequence of DM2 is unclear.62 Dapagliflozin is a highly selective and potent reversible inhibitor of SGLT2.63 By inhibiting the reabsorption of up to 50% of filtered glucose, it induces glycosuria of ~70 g/day, reducing fasting serum glucose by ~1 mmol/L compared with placebo.15 Greater reductions in PPG than fasting glucose are observed, suggesting renal excretion as one of the physiologic mechanisms in maintaining euglycemia after eating.15,64 In patients with baseline glycosuria due to poorly-controlled diabetes, the glucose-lowering effects of this medication are not attenuated; mean HbA1c and fasting glucose reductions with dapagliflozin were much higher in those with baseline HbA1c ≥10.1%.65 Hyperinsulinemic euglycemia clamp studies suggest that dapagliflozin improves insulin resistance,61 whereas HOMA-β assessments in phase III trials
demonstrate improved β-cell function, purportedly through decreased weight and glucotoxicity.66

Pharmacokinetics
Dapagliflozin is rapidly absorbed with 78% oral bioavailability,67 reaches peak plasma levels by 2 hours,64 and has a half-life of 12.9 hours.68 In ascending dose studies, near-maximal rates of glycosuria are induced with dapagliflozin 20 mg daily or higher, with sustained 3 g/h excretion for at least 24 hours in healthy and diabetic subjects.64 Its metabolism is catalyzed by multiple CYP enzymes, placing it at a low risk for drug interactions.64 The drug is mainly inactivated by the hepatic UGT1A9 enzyme;67 although the metabolism is catalyzed by multiple CYP enzymes, placing it at a low risk for drug interactions.64 The drug is mainly inactivated by the hepatic UGT1A9 enzyme;67 although the metabolite BMS-511926 is active, it is not produced unless dapagliflozin ≥50 mg is used.64 Half-life of the parent drug is 16 hours, with <2.5% of the drug excreted in the urine.64 Dapagliflozin was approved by the FDA in 2014 for the treatment of DM2 inadequately controlled by lifestyle modification.67 Usual dose is 5 mg or 10 mg daily, as higher doses have been associated with tolerability and safety issues.59 Use is contraindicated in the setting of moderate renal impairment (CrCl < 60 mL/min/1.73 m²).70

Clinical efficacy (dapagliflozin)

Monotherapy
In phase III clinical trials of treatment-naive DM2 patients, dapagliflozin 5 mg and 10 mg produced mean placebo-adjusted HbA1c reductions of approximately −0.54% and −0.66%, respectively, in studies up to 24 weeks.15,65 When followed to 102 weeks, Bailey et al1 found sustained placebo-adjusted HbA1c reductions of −0.69% (95% CI: −1.37, 0.02; p = 0.44) and −1.12% (95% CI: −1.79, −0.44; p = 0.001), respectively, even though metformin 500 mg daily was added to placebo at week 25 for ethical reasons. Mean fasting serum glucose reductions were seen as early as 1 week, achieving −1 mmol/L beyond placebo effects.15,65,71 Furthermore, dapagliflozin efficacy was similar to metformin monotherapy for HbA1c and FBG reduction at 12 weeks.15 Although at 24 weeks dapagliflozin 5 mg and 10 mg resulted in mean baseline weight reductions of −2.8 kg and −3.2 kg, respectively, compared with −2.2 kg in placebo group,65 follow-up to 102 weeks showed that only dapagliflozin 10 mg produced sustained and significant placebo-adjusted mean weight loss of −2.60 kg (95% CI: −4.70, −0.49; p = 0.016).71 Despite its mild diuretic effect, clinical trials using dual-energy X-ray absorptiometry demonstrated that weight loss with dapagliflozin is attributable to fat reduction.72,73

Add-on therapy
Dapagliflozin is also effective at further lowering HbA1c when added to other antihyperglycemics including secretagogues,74,75 metformin,76–78 pioglitazone,79 DPP4 inhibitors,80,81 α-glucosidase inhibitors,76 and insulin.82–84 When added to metformin, glimepiride, metformin/sitagliptin, or pioglitazone, dapagliflozin 5 mg and 10 mg produced placebo-adjusted mean HbA1c reductions of 0.40%–0.49% and 0.54%–0.68% at 24 weeks, respectively,75,76,79,80 with sustained if not greater reductions at 48 weeks.74,79 Mean FBG decreased by 0.86–1 mmol/L beyond placebo.75,76,79 A further 11%–17% and 15%–18% of patients on dapagliflozin 5 mg and 10 mg achieved HbA1c targets of <7% than placebo at 24 weeks,75,79 maintained at 48 weeks.74 Despite the weight-promoting effects of sulfonylureas, add-on dapagliflozin allowed for mean weight reductions from baseline; the 5 mg and 10 mg doses resulted in placebo-adjusted mean weight loss of −0.77 kg and −1.64 kg, respectively.74 With pioglitazone, although mean weight was mildly increased from baseline, add-on dapagliflozin had a sustained weight-sparing effect, with placebo-adjusted weight changes of −1.64 kg and −2.3 kg at 48 weeks, depending on dose;79 less peripheral edema was reported in treatment groups (4.3% for 5 mg and 2.1% for 10 mg) compared with placebo (6.5%).79

Wilding et al82 randomized 808 patients on moderate insulin therapy (mean TDD = 73.7–79.6 U) and up to two oral antihyperglycemic agents to dapagliflozin add-on or placebo. Despite longstanding disease (mean 13.6 years), HbA1c reduction was evident as early as 4 weeks, and by 24 weeks, placebo-adjusted mean HbA1c reductions in dapagliflozin 5 mg and 10 mg were −0.49% (95% CI: −0.65, −0.34; p < 0.001) and −0.57% (95% CI: −0.72, −0.42; p < 0.001), respectively, and maintained at 48 weeks.82 Subanalysis found that patients on insulin and oral agents at baseline attained a numerically greater placebo-adjusted HbA1c reduction (48 weeks, dapagliflozin 5 mg −0.58% [95% CI: −0.79, −0.37], dapagliflozin 10 mg −0.61% [95% CI: −0.82, −0.40]) than those on baseline insulin alone (48 weeks, dapagliflozin 5 mg −0.39% [95% CI: 0.63, −0.15], dapagliflozin 10 mg −0.46% [95% CI: −0.71, −0.21]).82 Extended follow-up to 104 weeks found that placebo-adjusted HbA1c reduction maintained significance at −0.40% with dapagliflozin (95% CI: −0.6, −0.2; p < 0.001).84 Insulin requirements decreased steadily with both dapagliflozin doses, with placebo-adjusted TDD change of −19.2 U (95% CI: −25.5, −12.9; p < 0.0001) for dapagliflozin 10 mg at 104 weeks.84 Weight loss was evident as early as 1 week, with placebo-adjusted mean change of −1.82 kg (95% CI: −2.56, −1.07; p < 0.001) and...
−2.43 kg (95% CI: −3.18, −1.68; p<0.001), respectively, at 48 weeks. By 104 weeks, placebo-adjusted weight reduction was maintained, with mean −3.33 kg (95% CI: −4.38, −2.27; p<0.0001) in the 10 mg cohort.

Long-term efficacy was established by Del Prato et al. comparing dapagliflozin with glipizide add-on to metformin over 4 years, as an extension of the 104-week study by Nauck et al. Although the mean HbA1c change from baseline of −0.52% at 52 weeks was gradually attenuated by 4 years (−0.10% [95% CI: −0.25, 0.05]), the glipizide-adjusted difference was sustained (2 years: −0.18% [95% CI: −0.33, −0.03]; 4 years: −0.30% [95% CI: −0.51, −0.09]). Mean weight loss in the dapagliflozin group at 104 weeks was −3.7 kg (95% CI: −4.2, −3.2), producing a glipizide-adjusted difference of −5.1 kg (95% CI: −5.7, −4.4) sustained at 4 years.

Safety/tolerability

Across various phase III trials, dapagliflozin was generally well tolerated with similar rates of adverse events as comparator and unlikely to lead to discontinuation. Adverse events of special interest include hypoglycemia, hypotension, renal dysfunction, and genitourinary tract infections as related to the mechanism of action of dapagliflozin.

Hypoglycemia frequency with dapagliflozin is low and comparable to other therapies, typically <4%, and unlikely to be severe. Notable exceptions are when this medication is added to sulfonylureas or insulin, due to the intrinsic propensity of these medications for hypoglycemia. When added to glimepiride, Strojek et al. found that a higher proportion of dapagliflozin-treated patients experienced hypoglycemia at 48 weeks (5 mg dose 10.3%, 15/145; 10 mg dose 11.3%, 17/151) than placebo (6.8%, 10/146). In their proof-of-concept study of dapagliflozin add-on to insulin, Wilding et al. found an increased prevalence of hypoglycemia (10 mg 29.2%, 7/24) compared with placebo (13.0%, 3/23) at 12 weeks, despite both cohorts having prophylactically reduced their TDD by 50%. In their subsequent study of 808 patients on insulin followed to 104 years however, incidence of hypoglycemia was not increased with dapagliflozin-insulin (60.7%, 119/196) compared with placebo—insulin (61.9%, 122/197), and most were not severe. Compared with glipizide add-on to metformin, dapagliflozin add-on had consistently lower hypoglycemia rates over 4 years (5.4% [22/406] compared to 51.5% [210/408]).

Owing to the mild diuretic effect of dapagliflozin, concerns have been raised about the potential for hypotension, hypovolemia, and renal impairment. In monotherapy and combination therapy trials, dapagliflozin lowered systolic blood pressure by a mean of 2.4–7.5 mmHg and diastolic blood pressure by 2.9–4.0 mmHg. However, these were not associated with rebound tachycardia, decreased eGFR, or increased hypotensive/hypovolemic event rates even after 4 years. Pooled analysis of 12 placebo-controlled trials found volume-related events to be low (dapagliflozin 0.8% [27/3, 291], placebo 0.4% [5/1, 393]); risks were higher in patients concomitantly treated with loop diuretics (6.1% versus 1.8%). Majority of reported renal events are laboratory based, and pooled analysis of studies up to 102 weeks showed a 2.0% event rate with dapagliflozin compared with 1.6% with placebo. There is often a mild, transient, and reversible decrease in eGFR in the first few weeks after initiation, consistent with a mild osmotic diuresis. Some evidence suggests that dapagliflozin may be renoprotective. Heerspink et al. performed a post hoc analysis of phase III clinical trials involving patients with poorly controlled diabetes and hypertension with nephropathy despite angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB). A total of 356 patients were identified with mean baseline eGFR 84 mL/min/1.73 m² and uACR of 76.5 mg/g. After 12 weeks of randomization to dapagliflozin 10 mg, the treatment group saw a placebo-adjusted decrease in albuminuria of −33.2% (95% CI: −45.4, −18.2) comparable to other SGLT2 inhibitors. In all, 40.5% of the dapagliflozin cohort improved from micro- to macroalbuminuria to a lower category compared with only 23.9% placebo. Multiple regression analysis showed that median change in HbA1c, systolic blood pressure, body weight, and eGFR was low (r²=11.5%, p<0.0001), suggesting that the albuminuria change is independent of these. SGLT2 inhibitors reduce intraglomerular pressure by a different mechanism as ACEi/ARB, and as this has been associated with long-term renal preservation, the authors proposed that dapagliflozin may have this long-term benefit. NCT02547935 is an upcoming trial of dapagliflozin in patients with chronic kidney disease and will help answer this hypothesis.

Although diabetes itself is associated with increased genital infections, incidence is increased with dapagliflozin use. Pooled analysis of 12 placebo-controlled studies found that 5.1% (167/3, 291) of patients on dapagliflozin 2.5–10 mg experienced genital infections compared with only 0.9% on placebo (12/1, 393), without dose-dependent effect. Most common events were vulvovaginal mycotic infections, and risk was increased in both males and females. However, overall risk increase was highest in females and those with a history of recurrent vulvovaginal infections; small increases were also noted for patients aged <65 years.
and with body mass index (BMI) ≥30. Time to first event was typically within the first 24 weeks. Infections were usually mild or moderate, responded to standard therapy, and rarely required discontinuation of therapy. In their pooled analysis, Ptaszynska et al found that only 4.3% of events in dapagliflozin-treated patients required repeat treatment; recurrence rates were low for both placebo (8.3%) and treatment (17.4%) arms. A smaller, increased incidence for urinary tract infections (UTIs) is also seen with dapagliflozin. Pool analysis found reported symptoms suggestive of UTIs in 4.8% of dapagliflozin-treated patients (158/3, 291) compared with 3.7% of placebo-treated patients (32/1, 393), without dose-dependent relationship. Where cultures were performed, typical pathogens were identified. Subgroup analysis showed more events occurred in women and patients aged ≥65 years. Although a history of recurrent UTIs increased incidence (17.1–21.1%) compared to those without (3.2–5.5%), use of dapagliflozin did not increase the risk further. Events were typically mild or moderate, occurring within the first 24 weeks, and required only one course of antibiotics without the need for dapagliflozin discontinuation. Pyelonephritis was a rare complication, and in their 14-study pooled analysis up to 102 weeks, Ptaszynska et al found only three cases (0.1%) with dapagliflozin compared with three cases (0.2%) with placebo.

Pooled analysis of short-term studies found a small mean percentage increase in fasting low-density lipoprotein (LDL) with dapagliflozin (0.6%–2.7%) versus placebo (−1.9%) and an increase in high-density lipoprotein (HDL; 3.8%–6.5% vs 3.8%, respectively). This was also observed by Wilding et al in their 104-week study, with increased mean HDL (dapagliflozin 5/10 mg 13.8% [95% CI: 7.1, 20.8] and 10 mg 7.3% [95% CI: 4.2, 10.4], placebo 5.1% [95% CI: −0.8, 11.3]) and a small increase in LDL (dapagliflozin 5/10 mg 5.0% [95% CI: −1.8, 12.2] and 10 mg 1.7% [95% CI: −4.0, 7.7], placebo −3.4% [95% CI: −9.1, 2.7]) from baseline. The mechanism for this drug effect has not been fully elucidated. In diet-induced hyperlipidemic hamsters, treatment with SGLT2 inhibitor empagliflozin resulted in a 25% increase in LDL during fasting states only. This was associated with a 116% increase in ketone bodies and a 49% increase in free fatty acids, demonstrating the increased lipid catabolism seen in human beings with prolonged SGLT2 inhibitor use. This shift from glucose to fat oxidation has also been demonstrated in patients on dapagliflozin after only 2 weeks, and this likely accounts for the small changes seen in lipid levels.

However, no signal of increased cardiovascular risk has been associated with these changes. A meta-analysis of 21 phase IIb/III clinical trials examining cardiovascular outcomes in 5,936 patients exposed to dapagliflozin (6,668 patient-years) and 3,403 controls (3,882 patient-years) found no increased risk for major adverse cardiovascular event (MACE) outcomes (HR = 0.72; 95% CI: 0.543, 1.097) or MACE with unstable angina (HR = 0.787; 95% CI: 0.579, 1.070). Risk ratio remained equivocal in subgroup analyses with high-risk patients aged ≥65 years. There was a signal for protective effect against hospitalization for heart failure in the treatment group (HR = 0.361; 95% CI: 0.156, 0.838). In a separate systematic review and meta-analysis, SGLT2 inhibitor use was protective for MACE (relative risk [RR] = 0.84; 95% CI: 0.75, 0.95; F = 43%) and MACE-plus (RR = 0.85; 95% CI: 0.77–0.95; F = 24%), largely driven by the results of EMPA-REG. However, dapagliflozin-specific data also showed benefit for MACE (RR = 0.67; 95% CI: 0.48, 0.94) and MACE-plus (RR = 0.69; 95% CI: 0.51, 0.92). Mechanism for these cardioprotective effects appears disproportionate to the glycemic benefits and is likely multifactorial. Some authors attribute it to the lowering of blood pressure, weight loss, and mild diuretic benefits; others note that these effects are small and the nonsignificant increase in stroke seems inconsistent with blood pressure control as a primary mechanism. Recently, a small, open-label, prospective study of DM2 patients on oral antihyperglycemic agents found that the addition of dapagliflozin specifically increased the large buoyant fraction of LDL cholesterol, with a decrease in the proportion of small dense LDL; the latter is more atherogenic and strongly associated with coronary artery disease. Therefore, although dapagliflozin has been associated with minor increases to LDL by inducing a shift from glucose to lipid catabolism, there is no associated increase in cardiovascular risk; in fact, evidence suggests dapagliflozin may be protective, possibly related to the composition. DECLARE-TIMI 58 (NCT01730534) – a large, prospective, randomized, and placebo-controlled study on cardiovascular outcomes with dapagliflozin – followed for up to 6 years – will better clarify this issue.

In 2016, the FDA strengthened its label warning for SGLT2 inhibitor use and the development of diabetic ketoacidosis (DKA), in response to 73 reported cases between 2013 and 2015. This concern prompted a position statement by the AACE. It highlighted a preexisting ketoacidosis event rate of 0.32–2.0/1,000 patient-years in DM2 patients compared with 0.2–0.8/1,000 patient-years in large clinical trials with SGLT2 inhibitors, suggesting that incidence may
not actually be increased with SGLT2 inhibitor use. Safety analyses from pooled dapagliflozin clinical trials did not identify any increased risk for DKA, and 2- and 4-year follow-up studies did not identify any events. AACE committee reviewed the DKA cases, and most occurred in patients with insulin deficiency, including long-standing DM2. Cases were often associated with very low carbohydrate diets or times of stress (i.e. surgery) when lipolysis and counterregulatory hormones are increased. Owing to their mechanism of action, SGLT2 inhibitors can induce DKA with lower-than-expected glucose levels, and clinical suspicion must remain high in patients with classical symptoms even without hyperglycemia. DKA risk should be minimized by holding SGLT2 inhibitors at least 24 hours before predictable stress and during acute illness, avoiding very low carbohydrate diets or excessive alcohol, and avoiding routine or excessive insulin reduction with drug initiation in patients with insulin-dependent DM2. However, the risk–benefit ratio still greatly support the use of this medication in DM2.

**Dapagliflozin/saxagliptin combination**

The combination pill comprising dapagliflozin/saxagliptin 10 mg/5 mg once daily is approved for management of type 2 diabetes in the United States and Europe. In the United States, this drug can be initiated for patients with inadequate glycemic control despite dapagliflozin 10 mg, or are already on free combination of the two medications, whereas in Europe, it is only approved for patients with inadequate control on metformin, a sulfonylurea and a monocomponent of the pill. Use is contraindicated in patients with moderate–severe renal impairment, defined as eGFR <45 mL/min/1.73 m² by the FDA.

**Efficacy**

In total, five completed phase III trials have examined the efficacy and safety of combined dapagliflozin and saxagliptin use in diabetes management; key demographic and baseline characteristics are summarized in Table 1. The key primary and secondary end points are summarized in Table 2, with relevant safety results summarized in Table 3A and B.

In the first of these trials, Rosenstock et al randomized 534 patients with diabetes poorly controlled with metformin monotherapy, to dapagliflozin/saxagliptin add-on versus saxagliptin 5 mg or dapagliflozin 10 mg single add-on. Baseline median HbA1c was 8.9% with a mean duration of disease of 7.6 years. After 24 weeks, mean adjusted HbA1c change with combined add-on was −1.47% (95% CI: −1.62, −1.31), significantly greater than with saxagliptin (−0.88%; 95% CI: −1.31, −0.44).

### Table 1: Baseline demographic and characteristics of the five phase III trials of dapagliflozin/saxagliptin compared with saxagliptin or dapagliflozin added to metformin baseline therapy

<table>
<thead>
<tr>
<th>Trial, year</th>
<th>n</th>
<th>Follow-up (weeks)</th>
<th>Duration of diabetes (years)</th>
<th>HbA1c (%)</th>
<th>BMI (kg/m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rosenstock et al</td>
<td>534</td>
<td>24</td>
<td>7.6</td>
<td>8.94 ±0.88</td>
<td></td>
</tr>
<tr>
<td>Matthaei et al</td>
<td>315</td>
<td>24</td>
<td>5.3</td>
<td>7.91 ±0.88</td>
<td></td>
</tr>
<tr>
<td>Mathieu et al</td>
<td>297</td>
<td>24</td>
<td>5.3</td>
<td>8.20 ±0.97</td>
<td></td>
</tr>
<tr>
<td>Mathieu et al</td>
<td>320</td>
<td>24</td>
<td>5.3</td>
<td>7.91 ±0.98</td>
<td></td>
</tr>
<tr>
<td>Mathieu et al</td>
<td>294</td>
<td>24</td>
<td>5.3</td>
<td>8.20 ±0.97</td>
<td></td>
</tr>
</tbody>
</table>

Notes: Paired trials are shaded to match with the same baseline characteristics. Mean ± SD unless otherwise specified. Number (percentage of total study population). Dapagliflozin 10 mg daily, saxagliptin 5 mg daily.

**Abbreviations:** BMI, body mass index; HbA1c, hemoglobin A1C; TDD, total daily dose; SD, standard deviation.
### Table 2: Key primary and secondary outcomes from five phase III trials of dapagliflozin/saxagliptin compared with saxagliptin or dapagliflozin added to metformin baseline therapy

<table>
<thead>
<tr>
<th>Trial, year</th>
<th>Comparison</th>
<th>Adj HbA1c Δ (%)</th>
<th>HbA1c &lt;7%</th>
<th>Adj FBG Δ (%)</th>
<th>Adj PPG Δ (%)</th>
<th>Adj FBG (mmol/L)</th>
<th>Adj PPG (mmol/L)</th>
<th>WT Δ (kg)</th>
<th>SBP Δ (mmHg)</th>
<th>DBP Δ (mmHg)</th>
<th>LDLΔ (%)</th>
<th>HDLΔ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rosenstock et al. 2015</td>
<td>Metformin + Saxa + Dapa</td>
<td>–1.47% (–1.62, –1.31)</td>
<td>41% (34.5, 48.2)</td>
<td>–2.11 (–2.40, –1.79)</td>
<td>–4.44 (–4.79, –4.04)</td>
<td>–2.1 (–2.5, –1.6)</td>
<td>–1.9 ± 1.2</td>
<td>–1.0 ± 0.8</td>
<td>3.7 (–0.9, 8.6)</td>
<td>5.4 (3.0, 7.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metformin + saxagliptin</td>
<td>–0.88% (–1.03, –0.72)</td>
<td>18% (130.2, 235)</td>
<td>–0.78 (–1.09, –0.47), NT</td>
<td>–2.0 (–2.36, –1.59)</td>
<td>0 (–0.5, 0.5)</td>
<td>0.3 ± 1.02</td>
<td>–0.4 ± 0.70</td>
<td>–0.6 (–5.1, 4.1)</td>
<td>0.9 (–1.4, 3.3)</td>
<td>p=0.009</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metformin + dapagliflozin</td>
<td>–1.20% (–1.35, –1.04)</td>
<td>22% (161.8, 283)</td>
<td>–1.78 (–2.07, –1.46), NT</td>
<td>–3.89 (–4.30, –3.53)</td>
<td>–2.4 (–2.9, –1.9)</td>
<td>–3.5 ± 1.29</td>
<td>–1.4 ± 0.84</td>
<td>1.5 (–3.1, 6.4)</td>
<td>7.7 (5.2, 10.2)</td>
<td>p=0.19</td>
<td></td>
</tr>
<tr>
<td>Matthieu et al. 2015</td>
<td>Metformin + dapagliflozin + saxagliptin</td>
<td>–0.51% (–0.63, –0.39)</td>
<td>35.3% (28.2, 42.4)</td>
<td>–0.50 (–0.79, –0.22)</td>
<td>–2.06 (–2.42, –1.71)</td>
<td>–0.53 (–)</td>
<td>– (–)</td>
<td>– (–)</td>
<td>–1.0 (–5.1, 3.4)</td>
<td>1.3 (–1.1, 3.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metformin + dapagliflozin</td>
<td>–0.16% (–0.28, –0.04)</td>
<td>23.1% (16.9, 23.9)</td>
<td>–0.28 (–0.58, 0.01), NT</td>
<td>–1.72 (–2.08, –1.39)</td>
<td>–0.51 (–)</td>
<td>– (–)</td>
<td>– (–)</td>
<td>1.5 (–2.7, 5.9)</td>
<td>0.1 (–2.3, 2.5)</td>
<td>p=0.2014</td>
<td></td>
</tr>
<tr>
<td>Matthieu et al. 2016</td>
<td>Metformin + dapagliflozin + saxagliptin</td>
<td>Between-group difference –0.42% (–0.64, –0.20)</td>
<td>29.3% (–)</td>
<td>Between-group difference –0.5 (–0.91, –0.006)</td>
<td>Between-group difference –0.5 (–0.91, –0.006)</td>
<td>–1.13 (–)</td>
<td>0.8 (–)</td>
<td>0.3 (–)</td>
<td>– (–)</td>
<td>– (–)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metformin + dapagliflozin</td>
<td>Between-group difference –0.42% (–0.64, –0.20)</td>
<td>13.1% (–)</td>
<td>Between-group difference –0.5 (–0.91, –0.006)</td>
<td>Between-group difference –0.5 (–0.91, –0.006)</td>
<td>–1.50 (–)</td>
<td>0.8 (–)</td>
<td>0.3 (–)</td>
<td>– (–)</td>
<td>– (–)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mathieu et al. 2015</td>
<td>Metformin + saxagliptin + dapagliflozin</td>
<td>–0.82% (–0.89, –0.75)</td>
<td>38% (30.9, 45.1)</td>
<td>–1.83 (–2.13, –1.51)</td>
<td>–4.11 (–4.53, –3.64)</td>
<td>–1.9 (–2.34, –1.48)</td>
<td>–1.9 (–1.7)</td>
<td>4.7 (0.9, 8.7)</td>
<td>6.2 (3.4, 9.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metformin + saxagliptin</td>
<td>–0.10% (–0.17, –0.03)</td>
<td>12.4% (7.0, 17.9)</td>
<td>–0.28 (–0.62, 0.03), p=0.0001</td>
<td>–2.11 (–2.56, –1.66), p=0.0001</td>
<td>–0.4 (–0.86, 0.04), p=0.0001</td>
<td>–0.4 (–2.3, 2.5)</td>
<td>2.8 (–0.9, 6.6)</td>
<td>2.8 (0.2, 5.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mathieu et al. 2016</td>
<td>Metformin + saxagliptin + dapagliflozin</td>
<td>–0.74% (–0.90, –0.57)</td>
<td>29.4% (22.7, 36.2)</td>
<td>–1.50 (–1.90, –1.08)</td>
<td>–2.1 (–2.70, –1.56)</td>
<td>–2.1 (–2.70, –1.56)</td>
<td>–2.1 (–2.70, –1.56)</td>
<td>– (–)</td>
<td>– (–)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metformin + saxagliptin</td>
<td>0.07% (–0.13, 0.27)</td>
<td>12.6% (7.4, 17.9)</td>
<td>0.56 (0.09, 1.04)</td>
<td>– (–)</td>
<td>–0.4 (–2.70, –1.56)</td>
<td>–0.4 (–2.70, –1.56)</td>
<td>– (–)</td>
<td>– (–)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: Paired trials are shaded to match. *Mean (95% CI). †Mean ± SD unless otherwise specified. p-Values reported are for difference relative to triple-therapy intervention. – denotes where data were not reported or could not be obtained from authors. To convert glucose from mmol/L to mg/dL, divide by 0.05556.

Abbreviations: Adj, adjusted from baseline; HbA1c, hemoglobin A1c; FBG, fasting blood glucose; PPG, post-prandial glucose; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CI, confidence interval; SD, standard deviation; Metf, metformin; Saxa, saxagliptin; Dapa, dapagliflozin; WT, weight; SBP, systolic blood pressure; DBP, diastolic blood pressure; NT, not tested under pre-specified sequential testing procedure of the respective studies.
Table 3  Total adverse events experienced by patients across (A) all five phase III trials comparing dapagliflozin/saxagliptin add-on therapy against either dapagliflozin- or saxagliptin-only add-on to metformin baseline therapy; and (B) only the three phase III trials at 24-week follow-up

A

<table>
<thead>
<tr>
<th>Trial, year</th>
<th>Comparison [n]</th>
<th>≥1 AE</th>
<th>≥1 Serious AEs</th>
<th>AEs leading to discontinuation</th>
<th>UTI</th>
<th>Genital infection</th>
<th>All-reported hypoglycemia</th>
<th>Volume depletion</th>
<th>Heart failure</th>
<th>eGFR decrease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rosenstock et al [99] 2015</td>
<td>Metformin + saxagliptin + dapagliflozin [179]</td>
<td>87 (49)</td>
<td>2 (1)</td>
<td>1 (0.6)</td>
<td>1 (0.6)</td>
<td>0 (0)</td>
<td>2 (1)</td>
<td>–</td>
<td>–</td>
<td>3 (2)</td>
</tr>
<tr>
<td>Metformin + saxagliptin [176]</td>
<td>93 (53)</td>
<td>6 (3)</td>
<td>0 (0)</td>
<td>9 (5)</td>
<td>1 (0.6)</td>
<td>2 (1)</td>
<td>–</td>
<td>–</td>
<td>1 (0.6)</td>
<td></td>
</tr>
<tr>
<td>Metformin + dapagliflozin [179]</td>
<td>87 (49)</td>
<td>2 (1)</td>
<td>1 (0.6)</td>
<td>7 (5)</td>
<td>10 (6)</td>
<td>2 (1)</td>
<td>–</td>
<td>–</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Matthaei et al [100] 2015</td>
<td>Metformin + dapagliflozin + saxagliptin [153]</td>
<td>73 (47.7)</td>
<td>5 (3.3)</td>
<td>1 (0.7)</td>
<td>8 (5.2)</td>
<td>0 (0)</td>
<td>2 (1.3)</td>
<td>0 (0)</td>
<td>1 (0.7)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Metformin + dapagliflozin [162]</td>
<td>70 (43.2)</td>
<td>5 (3.1)</td>
<td>3 (1.9)</td>
<td>6 (3.7)</td>
<td>4 (2.5)</td>
<td>4 (2.5)</td>
<td>2 (1.2)</td>
<td>2 (1.2)</td>
<td>2 (1.2)</td>
<td></td>
</tr>
<tr>
<td>Matthaei et al [101] 2016</td>
<td>Metformin + dapagliflozin + saxagliptin [153]</td>
<td>89 (58.2)</td>
<td>7 (4.6)</td>
<td>3 (2.0)</td>
<td>12 (7.8)</td>
<td>5 (3.3)</td>
<td>2 (1.3)</td>
<td>1 (0.7)</td>
<td>1 (0.7)</td>
<td>2 (1.3)</td>
</tr>
<tr>
<td>Metformin + dapagliflozin [162]</td>
<td>94 (60.0)</td>
<td>11 (6.8)</td>
<td>5 (3.1)</td>
<td>12 (7.4)</td>
<td>10 (6.2)</td>
<td>4 (2.5)</td>
<td>3 (1.9)</td>
<td>4 (2.5)</td>
<td>2 (1.2)</td>
<td></td>
</tr>
<tr>
<td>Mathieu et al [102] 2015</td>
<td>Metformin + saxagliptin + dapagliflozin [160]</td>
<td>90 (56.3)</td>
<td>5 (3.1)</td>
<td>8 (5.0)</td>
<td>12 (7.8)</td>
<td>5 (3.3)</td>
<td>2 (1.3)</td>
<td>–</td>
<td>2 (1.3)</td>
<td>2 (1.3)</td>
</tr>
<tr>
<td>Metformin + saxagliptin [160]</td>
<td>94 (58.8)</td>
<td>3 (1.9)</td>
<td>2 (1.3)</td>
<td>10 (6.3)</td>
<td>1 (0.6)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Mathieu et al [103] 2016</td>
<td>Metformin + saxagliptin + dapagliflozin [160]</td>
<td>106 (66.3)</td>
<td>7 (4.4)</td>
<td>9 (5.6)</td>
<td>15 (9.4)</td>
<td>10 (6.3)</td>
<td>3 (1.9)</td>
<td>–</td>
<td>3 (1.9)</td>
<td>5 (3.1)</td>
</tr>
<tr>
<td>Metformin + saxagliptin [160]</td>
<td>114 (71.3)</td>
<td>4 (2.5)</td>
<td>3 (1.9)</td>
<td>16 (10)</td>
<td>2 (1.3)</td>
<td>0 (0)</td>
<td>–</td>
<td>2 (1.3)</td>
<td>3 (1.9)</td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>Study</th>
<th>Comparison [n]</th>
<th>≥1 AE</th>
<th>≥1 Serious AEs</th>
<th>AEs leading to discontinuation</th>
<th>UTI</th>
<th>Genital infection</th>
<th>All-reported hypoglycemia</th>
<th>Volume depletion</th>
<th>Heart failure</th>
<th>eGFR decrease</th>
</tr>
</thead>
<tbody>
<tr>
<td>24-week</td>
<td>Metformin + saxagliptin + dapagliflozin [492]</td>
<td>250 (50.8)</td>
<td>12 (2.4)</td>
<td>10 (2.0)</td>
<td>17 (3.5)</td>
<td>8 (1.6)</td>
<td>6 (1.2)</td>
<td>–</td>
<td>–</td>
<td>5 (1.0)</td>
</tr>
<tr>
<td>follow-up</td>
<td>Metformin + saxagliptin [336]</td>
<td>187 (55.7)</td>
<td>9 (2.7)</td>
<td>2 (0.6)</td>
<td>19 (5.7)</td>
<td>2 (0.6)</td>
<td>2 (0.6)</td>
<td>–</td>
<td>–</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>up [99,101,102]</td>
<td>Metformin + dapagliflozin [341]</td>
<td>157 (46.0)</td>
<td>7 (2.1)</td>
<td>4 (1.2)</td>
<td>13 (3.8)</td>
<td>14 (4.1)</td>
<td>6 (1.8)</td>
<td>–</td>
<td>–</td>
<td>2 (0.6)</td>
</tr>
</tbody>
</table>

**Notes:** (A) Paired trials are shaded to match. [n] is the number of patients exposed to at least one dose of the assigned therapy, excluding patients who have been exposed to rescue medication during study. All event data are n (%) of the treatment arm. – denotes data that are not reported. (B) Data from identical treatment arms were summed across the studies only if data are available for all three trials to avoid reporting bias. [n] is the total number of patients across all three studies with reported data. All events are reported as n (%) of the treatment arm. *Insufficient data for summation.

**Abbreviations:** AE, adverse event; UTI, genitourinary tract infection; eGFR, estimated glomerular filtration rate.
1.03, −0.72; \( p<0.0001 \)) or dapagliflozin alone (−1.20%; 95% CI: 1.35, −1.04; \( p=0.0166 \)). \(^{99} \) A total of 41% of the patients on dapagliflozin/saxagliptin achieved target HbA1c of <7%, compared with only 18% of patients on saxagliptin and 22% of those on dapagliflozin. \(^{99} \) PPG and fasting plasma glucose were also lower than with single add-on therapy. Weight reduction by combined treatment was −2.1 kg (95% CI: −2.5, −1.6), due to the effects of dapagliflozin. \(^{99} \)

Matthaei et al \(^{100} \) examined the effects of dapagliflozin/saxagliptin added to metformin compared with dapagliflozin alone after 24 weeks with a 52-week extended study. \(^{101} \) In the initial study, 431 patients with HbA1c between 8.0% and 11.5% despite stable-dose metformin completed a 16-week run-in period with open-label dapagliflozin 10 mg add-on. \(^{101} \) A total of 315 (73%) patients ultimately entered double-blind randomization to saxagliptin 5 mg or placebo; of the 116 patients not randomized, 82% did not meet inclusion criteria as HbA1c had improved to <7% with dapagliflozin alone. \(^{101} \) Glucose-lowering benefits of dapagliflozin/saxagliptin were evident by as early as 6 weeks after randomization and persisted until the end of study. Mean adjusted HbA1c change with dapagliflozin/saxagliptin (−0.51%; 95% CI: −0.63, −0.39) was greater than dapagliflozin alone (−0.16%; 95% CI: −0.28, −0.04; \( p<0.0001 \)). \(^{101} \) This between-group difference was maintained at 52 weeks (−0.42%; 95% CI: −0.64, −0.20). \(^{101} \) Postprandial glycemic control was assessed using a standardized liquid meal tolerance test, and although the mean adjusted reduction was numerically greater in the dapagliflozin/saxagliptin group at 24 weeks, it was not statistically significant (\( p=0.2014 \)). \(^{101} \) Weight reduction was similar between the two groups, \(^{100,101} \) which is expected given that saxagliptin is weight neutral.

Mathieu et al \(^{102} \) performed a complementary study examining the efficacy of triple therapy compared with saxagliptin alone in a 24-week study, with follow-up to 52 weeks. \(^{103} \) The trial included two strata of patients with poorly controlled DM2: strata A patients were on stable metformin therapy and strata B patients were on stable metformin as well as any maxim-dose DPP4 inhibitor. Strata A patients underwent a 16-week run-in with added open-label saxagliptin 5 mg, whereas strata B patients had their baseline DPP4 inhibitor switched to saxagliptin 5 mg during an 8-week run-in. Ultimately, a total of 320 patients were then randomized to receive dapagliflozin 10 mg or placebo. By 24 weeks, the mean adjusted HbA1c was reduced by −0.82% in the dapagliflozin/saxagliptin group (95% CI: −0.89, −0.75) compared with only −0.10% reduction in the saxagliptin-only group (95% CI: −0.17, −0.03; \( p<0.0001 \)). \(^{102} \) This was maintained at 52 weeks. \(^{103} \) Both FBG and PPG levels were reduced significantly in the combined treatment group at 24 weeks; \(^{102} \) this effect was attenuated at 1 year, although combined treatment still maintained a similar reduction in FBG. \(^{102} \) Weight was significantly reduced in the saxagliptin/dapagliflozin group by a mean of −1.9 kg (95% CI: −2.34, −1.48) compared with only −0.4 kg (95% CI: −0.86, 0.04; \( p<0.0001 \)) in the saxagliptin-only group \(^{102} \) and was maintained at 52-week follow-up. \(^{103} \)

**Tolerability and safety**
Across the five studies, blood pressure was only minimally decreased. \(^{99,103} \) The largest reported change was in the 24-week study by Rosenstock et al \(^{99} \) in which the dapagliflozin-only group saw a mean decrease of −3.5 mmHg in systolic blood pressure, but without events of hypovolemia. In the same study, LDL was also increased minimally from baseline in patients on dapagliflozin, the largest increase being +3.7% in the triple-therapy group (95% CI: −0.9, 8.6), \(^{99} \) but was statistically nonsignificant compared with the other two treatment arms. These changes are consistent with those seen in other phase III dapagliflozin studies, with no signal toward increased coronary events. \(^{51,101} \)

Adverse events were low across the studies and similar between treatment arms (Table 3A). When totaled across all three 24-week studies (Table 3B), the proportion of serious adverse events remained low at 2.4% (12/492 patients) in the triple therapy arms, \(^{99,101,102} \) 2.1% (7/341) in the dapagliflozin-only arm, \(^{99,101} \) and 2.7% (9/336) in saxagliptin-only arm. \(^{99,102} \) Discontinuation rate for dual add-on therapy was generally low and comparable to single add-on therapy. \(^{99,101,102} \) Mathieu et al \(^{102} \), however, found higher rates of discontinuation with triple therapy than with saxagliptin-alone therapy, at 24 weeks (5% vs 1.3%) and 52 weeks (5.6% vs 1.9%). \(^{103} \) There was no clear trend to account for the increased rate seen in their studies. Hypoglycemia was low across all five phase III trials, ranging from 0% to 2.5%. \(^{99,103} \) When examining results from all three 24-week follow-up studies, 1.2% (6/492) of dapagliflozin/saxagliptin patients experienced events consistent with hypoglycemia compared with 1.8% (6/341) of patients in the dapagliflozin-only group and 0.6% (2/336) of patients in the saxagliptin-only group. \(^{99,102} \) No events of severe hypoglycemia occurred even at 52-week follow-up. \(^{100,103} \)

UTI rates were comparable between those on dapagliflozin/saxagliptin and those on single-treatment add-on. When the event rates were summed across the 24-week studies, 3.5% (17/492) \(^{99,101,102} \) of patients on triple therapy expe-
rienced a UTI compared with 3.8% (19/341)\textsuperscript{99,101} of patients on dapagliflozin alone and 5.7% (19/336) of patients on saxagliptin alone.\textsuperscript{99,102} Only one patient experienced recurrent vulvovaginal and UTIs requiring medication discontinuation, and this occurred in the dapagliflozin/saxagliptin arm.\textsuperscript{102} There was no report of pyelonephritis in any of the trials. Despite the recognized increased rate of genital infections associated with SGLT2 inhibitor use,\textsuperscript{68} a lower rate was observed across all trials in the combined dapagliflozin/saxagliptin arm than in the dapagliflozin-only group.\textsuperscript{99–101} At 24 weeks, infection rate was 1.6% (6/492 patients) in the dapagliflozin/saxagliptin group, 4.1% (14/341 patients) in dapagliflozin-only group, and 0.6% (2/336 patients) in saxagliptin-only group.\textsuperscript{99,102} This effect was still observed at 52-week follow-up,\textsuperscript{100} suggestive of a protective effect with combined therapy, although the mechanism is unclear. As in dapagliflozin trials, genital infections were more likely to occur in women. The remainder of adverse events was low and did not increase from individual therapy.

### Ongoing trials

As of February 2017, several studies are ongoing to examine the safety and efficacy of saxagliptin/dapagliflozin combination therapy. One phase III trial to be completed late 2017 will be comparing dual versus single saxagliptin or dapagliflozin add-on to metformin (NCT02681094). An exploratory phase II/III trial is being conducted for dapagliflozin with or without reduced dose of saxagliptin in patients with DM2 and documented chronic kidney disease (NCT02547935). The inclusion criterion includes eGFR 25–75 mL/min/1.73 m\textsuperscript{2} with micro- or macroalbuminuria already on an ACEi or ARB.

NCT02419612 and NCT02471404 will further examine the lasting efficacy of dapagliflozin/saxagliptin in extended follow-up, compared with sulfonylurea add-on for glycemic control. Two other trials are examining the role of combination therapy in conjunction with insulin. NCT02551874 will be comparing the adequacy of glycemic control using combined add-on versus basal insulin over 24 weeks in patients on baseline metformin with or without sulfonylurea. A phase IV trial (NCT02965443) will assess if addition of dapagliflozin/saxagliptin would negate the need for basal–bolus insulin. NCT02946632 is pending recruitment to compare the efficacy and benefit of initial metformin plus dapagliflozin/saxagliptin treatment compared with conventional, stepwise management of drug-naïve DM2 patients. These upcoming studies will better delineate the efficacy and tolerability of combination therapy but more importantly, will establish its role and timing in various diabetes subpopulations.

### Discussion

Owing to progressive β-cell dysfunction, DM2 patients often require multiple medications to maintain glycemic control over time.\textsuperscript{6} Furthermore, delayed initiation of multiple agents as required increases glucotoxicity and makes glycemic control more difficult.\textsuperscript{12} Many of the add-on agents have undesirable side effects, including weight gain, fluid retention, and/or increased risk of hypoglycemia. Both saxagliptin and dapagliflozin have been shown to produce glycemic benefits and are well tolerated. Importantly, they do not increase the risk of hypoglycemia, even when added to a variety of antihyperglycemic agents.\textsuperscript{85} Saxagliptin is weight neutral, and dapagliflozin can result in weight loss, important considerations given the high prevalence of obesity in this population.\textsuperscript{9} Furthermore, some evidence suggests that dapagliflozin may have renoprotective\textsuperscript{66} and cardiovascular\textsuperscript{93,94} benefits, both common comorbidities in patients with diabetes. Ongoing NCT02547935 trial for combination therapy in chronic kidney disease and NCT01730534 trial for dapagliflozin in cardiovascular outcomes will help clarify these benefits.

Although each medication can be used as individual add-on therapy, dual add-on therapy may be preferred over sequential add-on for those with poor glycemic control, as recommended by major diabetes guidelines.\textsuperscript{6,12,14} Furthermore, these two medications work in complementary mechanisms. Direct comparisons between SGLT2 and DPP4 inhibitors show that after 52 weeks, SGLT2 inhibitors consistently and more potently lower fasting glucose levels. Although both lower PPG, DPP4 inhibitors result in a greater decrement after taking into account their respective fasting glucose-lowering effects\textsuperscript{29} and inhibit the increased glucagon production seen with dapagliflozin.\textsuperscript{16,17} The five completed phase III trials have demonstrated additional glycemic-lowering benefit from combined dapagliflozin/saxagliptin add-on therapy, lowering mean HbA1c by as much as −1.47% (95% CI: −1.62, −1.31);\textsuperscript{99} without significant increase in adverse events even at 52-week follow-up.\textsuperscript{100,103} Dual add-on therapy resulted in weight loss of −0.5 kg to −2 kg, and may have a protective effect against the genital infections which can occur with dapagliflozin single add-on. For patients with long-standing or severe disease requiring insulin, evidence exists for adding saxagliptin and dapagliflozin, with more patients achieving HbA1c target with less insulin requirement and weight gain.\textsuperscript{46,84} These studies suggest that combined dapagliflozin/saxagliptin add-on to insulin is safe and advantageous.

STC pills have been used in many chronic illnesses such as cardiovascular disease, AIDS, and diabetes.\textsuperscript{19} Not only do they increase compliance, lower cost burden, and improve quality of life,\textsuperscript{19,21} they have been shown to minimize side
effects while improving glycemic control beyond loose-pill combinations. Other STC therapies in diabetes have been found to be safe and efficacious, including the other SGLT2/DPP4 inhibitor STC empagliflozin/linagliptin. In a review of existing phase III clinical trials using empagliflozin/linagliptin add-on to metformin, it lowered HbA1c by −1.19%±0.06% at the maximum dose after 24 weeks, comparable to dapagliflozin/saxagliptin with a similar safety profile.

**Conclusion**

The addition of dapagliflozin/saxagliptin takes advantage of complementary mechanisms of action and provides augmented glycemic control. The increased incidence of genital infection seen with dapagliflozin single add-on therapy is attenuated in combined add-on therapy, suggestive of a possible protective effect. It is otherwise well tolerated with a safety profile similar to single add-on therapy, and the risk of hypoglycemia remains low. Therefore, for patients in need of dual add-on therapy or with poorly controlled diabetes despite add-on with either monocomponent, initiation of dapagliflozin/saxagliptin combination is a safe and rational option.

**Disclosure**

Dr. Huan Yu has no potential conflicts of interest. Dr. Vincent C Woo has received funds from the following organizations for speaking, advisory boards, and/or clinical research: Astra Zeneca, Bristol Myers Squibb, Merck, Lilly, Novo Nordisk, Sanofi, Roche, Abbott, Boehringer Ingelheim, Pfizer, Janssen, and Novartis.

**References**


70. FDA Drug Label, editor. Farxiga (dapagliflozin); 2014; No. Reference ID: 3606617.


